ObjectiveHealth Launches Feasibility and Recruitment Platform, ObjectiveScreen
ObjectiveHealth has announced the launch of ObjectiveScreen, an AI feasibility and recruitment platform that seeks to provide patient identification, prequalification, and retention.
Powered by ObjectiveHealth’s cloud-based, AI and ML algorithms, ObjectiveScreen allows clinical trial sites to connect directly with patient electronic health records (EHRs). Patient health risks are stratified against evidence-based physiologic and molecular biomarkers so users can identify in the most qualified candidates for specific clinical trials.
Each time an EHR is linked, ObjectiveScreen’s algorithms analyze the health data, updating its clinical knowledge base while qualifying patients for the specific trials.
In addition to EHR analysis, ObjectiveScreen can review other patient data, including risk factors and demographic data such as age, gender, ethnicity and socioeconomic status, which can help identify candidates who may not have a diagnosis.
By linking with a healthcare provider’s scheduling application, users of ObjectiveScreen can arrange prescreen visits. ObjectiveScreen’s texting and calling capabilities allow clinical trial site users to communicate directly with patients about appointment reminders and rescheduling options. Users can also monitor patients over multiple visits and recommend new studies if patients did not qualify for a previous trial.
Reference
ObjectiveHealth Launches ObjectiveScreen, an Artificial Intelligence-Powered Feasibility and Recruitment Platform to Optimize Clinical Trial Performance. (2023, June 8). Business Wire.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
